Skip to content
OpenCapital
Get started

Prestige Consumer Healthcare PBH Analgesics — Total revenues

Other product segments

Gastrointestinal
$68.35M-0.8%
Women's Health
$57.05M-10.6%
Eye & Ear Care
$37.85M-19.0%
Dermatologicals
$30.49M+4.8%
Oral Care
$28M+3.3%
Cough & Cold
$26.29M-2.3%
Other OTC
$5.35M+39.2%

Similar metrics at other companies

Organon logo
OGNOther Non-Opiod Pain, Bone and Dermatology — Revenue
$68M0.0%
Bausch + Lomb logo
BLCOPharmaceuticals — Total revenues
$266M+19.8%
Gentex logo
GNTXMedical Products — Total Revenue
$353.62K-8.6%
Bausch + Lomb logo
BLCOBranded and Other Generics — Total revenues
$49M-9.3%
Bausch Health Companies logo
BHCProduct sales — Revenue
$2.5B+12.3%
Tarsus Pharmaceuticals, Inc. logo
TARSProduct sales, net — Total revenues
$145.39M+85.6%

Other financials

Income statement

See full
Revenue$281.6M-5.0%
Gross profit$146.3M-13.9%
Operating income$75.5M-14.6%
Net income$53.9M+7.6%
EPS (diluted)$1.13+11.9%

Balance sheet

See full
Cash & equivalents$63.9M-34.8%
Total debt$1.0B-0.2%
Total equity$1.9B+2.9%
Total assets$3.5B+2.7%

Cash flow

See full
Operating cash flow$42.8M-30.7%
CapEx$5.2M+49.8%
Free cash flow$37.6M-35.5%

Valuation

See full
Market cap$2.18B-34.1%
Enterprise value$3.16B-27.3%
P/E11.5×-4.0×
P/S2×-0.9×

Profitability

See full
Gross margin54.7%-1.1pp
Operating margin28.4%-1.2pp
Net margin17.5%-1.4pp
FCF margin22.6%+1.3pp

Returns & leverage

See full
Return on equity10.2%-2.1pp
Debt / equity0.6×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Prestige Consumer Healthcare in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Prestige Consumer Healthcare’s 10-K, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prestige Consumer Healthcare's analgesics — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prestige Consumer Healthcare's analgesics — total revenues?
Prestige Consumer Healthcare (PBH) reported analgesics — total revenues of $28.24M in Q1 2026.
How has Prestige Consumer Healthcare's analgesics — total revenues changed year-over-year?
Prestige Consumer Healthcare's analgesics — total revenues decreased by 6.5% year-over-year, from $30.2M to $28.24M.
What is the long-term trend for Prestige Consumer Healthcare's analgesics — total revenues?
Over 4 years (2022 to 2026), Prestige Consumer Healthcare's analgesics — total revenues has grown at a -1.1% compound annual growth rate (CAGR), from $119.32M to $113.94M.
What does analgesics — total revenues mean?
This metric represents the total gross sales generated from the analgesics product category, which includes over-the-counter pain relief medications. It serves as a key indicator of market demand and brand performance within the company's pain management portfolio. Tracking this revenue stream helps investors assess the segment's ability to maintain market share and drive growth within the broader consumer healthcare landscape.